Werewolf Current Deferred Revenue vs Common Stock Analysis

HOWL Stock

USD 2.05 0.01 0.49%

Werewolf Therapeutics financial indicator trend analysis is more than just analyzing Werewolf Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Werewolf Therapeutics is a good investment. Please check the relationship between Werewolf Therapeutics Current Deferred Revenue and its Common Stock accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.

Current Deferred Revenue vs Common Stock

Current Deferred Revenue vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Werewolf Therapeutics Current Deferred Revenue account and Common Stock. At this time, the significance of the direction appears to have pay attention.

The correlation between Werewolf Therapeutics' Current Deferred Revenue and Common Stock is -0.82. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Common Stock in the same time period over historical financial statements of Werewolf Therapeutics, assuming nothing else is changed. The correlation between historical values of Werewolf Therapeutics' Current Deferred Revenue and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Werewolf Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Current Deferred Revenue i.e., Werewolf Therapeutics' Current Deferred Revenue and Common Stock go up and down completely randomly.

Correlation Coefficient

-0.82

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Common Stock

Most indicators from Werewolf Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Werewolf Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.Sales General And Administrative To Revenue is expected to rise to 1.14 this year, although the value of Selling General Administrative will most likely fall to about 13.5 M.

	2021	2022	2023	2024 (projected)
Interest Expense	216K	1.1M	3.1M	3.3M
Depreciation And Amortization	216K	1.1M	1.8M	951.3K

Interest Expense Depreciation And Amortization

Werewolf Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.74	0.94	0.92	0.91	-0.96	0.92	0.94	-0.96	-0.94	0.93	1.0	0.84	0.78	0.47	1.0	0.72	0.5	-0.12	0.94	0.94	0.95	0.1	0.92	0.66	1.0
Short Long Term Debt Total	0.74		0.65	0.72	0.67	-0.69	0.82	0.7	-0.55	-0.87	0.62	0.7	0.98	0.51	0.03	0.7	0.76	0.89	-0.17	0.68	0.65	0.75	-0.01	0.73	0.97	0.7
Other Current Liab	0.94	0.65		0.98	0.91	-0.89	0.89	0.96	-0.9	-0.93	0.82	0.92	0.79	0.95	0.72	0.92	0.77	0.41	-0.27	0.94	0.97	0.95	-0.03	0.9	0.64	0.93
Total Current Liabilities	0.92	0.72	0.98		0.89	-0.85	0.89	0.95	-0.82	-0.95	0.74	0.88	0.84	0.93	0.68	0.88	0.88	0.55	-0.28	0.91	0.94	0.95	-0.03	0.9	0.73	0.9
Total Stockholder Equity	0.91	0.67	0.91	0.89		-0.77	0.97	0.99	-0.84	-0.92	0.89	0.89	0.8	0.85	0.54	0.89	0.69	0.4	-0.52	0.99	0.98	0.98	-0.31	0.99	0.59	0.9
Other Liab	-0.96	-0.69	-0.89	-0.85	-0.77		-0.8	-0.83	0.95	0.87	-0.88	-0.97	-0.78	-0.7	-0.43	-0.97	-0.64	-0.47	-0.13	-0.82	-0.84	-0.84	-0.35	-0.78	-0.63	-0.97
Net Tangible Assets	0.92	0.82	0.89	0.89	0.97	-0.8		0.97	-0.82	-0.97	0.88	0.89	0.92	0.81	0.43	0.89	0.72	0.55	-0.46	0.97	0.95	0.97	-0.26	0.97	0.75	0.9
Property Plant And Equipment Net	0.94	0.7	0.96	0.95	0.99	-0.83	0.97		-0.87	-0.96	0.88	0.92	0.83	0.9	0.61	0.92	0.75	0.44	-0.44	1.0	0.99	0.99	-0.21	0.98	0.64	0.93
Net Debt	-0.96	-0.55	-0.9	-0.82	-0.84	0.95	-0.82	-0.87		0.83	-0.95	-0.98	-0.68	-0.75	-0.52	-0.98	-0.52	-0.25	0.03	-0.88	-0.9	-0.86	-0.18	-0.82	-0.46	-0.98
Retained Earnings	-0.94	-0.87	-0.93	-0.95	-0.92	0.87	-0.97	-0.96	0.83		-0.84	-0.92	-0.95	-0.84	-0.46	-0.92	-0.82	-0.65	0.31	-0.94	-0.94	-0.97	0.08	-0.94	-0.83	-0.92
Accounts Payable	0.93	0.62	0.82	0.74	0.89	-0.88	0.88	0.88	-0.95	-0.84		0.95	0.73	0.65	0.32	0.95	0.46	0.29	-0.19	0.9	0.88	0.87	-0.01	0.88	0.48	0.95
Cash	1.0	0.7	0.92	0.88	0.89	-0.97	0.89	0.92	-0.98	-0.92	0.95		0.81	0.76	0.45	1.0	0.66	0.44	-0.07	0.92	0.93	0.92	0.15	0.89	0.61	1.0
Non Current Assets Total	0.84	0.98	0.79	0.84	0.8	-0.78	0.92	0.83	-0.68	-0.95	0.73	0.81		0.67	0.22	0.81	0.8	0.81	-0.26	0.82	0.79	0.87	-0.06	0.85	0.94	0.81
Non Currrent Assets Other	0.78	0.51	0.95	0.93	0.85	-0.7	0.81	0.9	-0.75	-0.84	0.65	0.76	0.67		0.87	0.76	0.72	0.27	-0.45	0.88	0.92	0.86	-0.23	0.82	0.54	0.78
Other Assets	0.47	0.03	0.72	0.68	0.54	-0.43	0.43	0.61	-0.52	-0.46	0.32	0.45	0.22	0.87		0.45	0.46	-0.13	-0.35	0.57	0.66	0.54	-0.17	0.48	0.12	0.48
Cash And Short Term Investments	1.0	0.7	0.92	0.88	0.89	-0.97	0.89	0.92	-0.98	-0.92	0.95	1.0	0.81	0.76	0.45		0.66	0.44	-0.07	0.92	0.93	0.92	0.15	0.89	0.61	1.0
Common Stock Total Equity	0.72	0.76	0.77	0.88	0.69	-0.64	0.72	0.75	-0.52	-0.82	0.46	0.66	0.8	0.72	0.46	0.66		0.8	-0.21	0.7	0.71	0.8	0.0	0.75	0.82	0.67
Common Stock Shares Outstanding	0.5	0.89	0.41	0.55	0.4	-0.47	0.55	0.44	-0.25	-0.65	0.29	0.44	0.81	0.27	-0.13	0.44	0.8		0.0	0.39	0.36	0.53	0.13	0.5	0.92	0.44
Non Current Liabilities Total	-0.12	-0.17	-0.27	-0.28	-0.52	-0.13	-0.46	-0.44	0.03	0.31	-0.19	-0.07	-0.26	-0.45	-0.35	-0.07	-0.21	0.0		-0.46	-0.41	-0.4	0.97	-0.48	-0.14	-0.09
Capital Lease Obligations	0.94	0.68	0.94	0.91	0.99	-0.82	0.97	1.0	-0.88	-0.94	0.9	0.92	0.82	0.88	0.57	0.92	0.7	0.39	-0.46		0.99	0.98	-0.24	0.98	0.6	0.93
Other Current Assets	0.94	0.65	0.97	0.94	0.98	-0.84	0.95	0.99	-0.9	-0.94	0.88	0.93	0.79	0.92	0.66	0.93	0.71	0.36	-0.41	0.99		0.98	-0.19	0.96	0.59	0.94
Other Stockholder Equity	0.95	0.75	0.95	0.95	0.98	-0.84	0.97	0.99	-0.86	-0.97	0.87	0.92	0.87	0.86	0.54	0.92	0.8	0.53	-0.4	0.98	0.98		-0.17	0.99	0.69	0.93
Total Liab	0.1	-0.01	-0.03	-0.03	-0.31	-0.35	-0.26	-0.21	-0.18	0.08	-0.01	0.15	-0.06	-0.23	-0.17	0.15	0.0	0.13	0.97	-0.24	-0.19	-0.17		-0.27	0.02	0.13
Net Invested Capital	0.92	0.73	0.9	0.9	0.99	-0.78	0.97	0.98	-0.82	-0.94	0.88	0.89	0.85	0.82	0.48	0.89	0.75	0.5	-0.48	0.98	0.96	0.99	-0.27		0.65	0.9
Property Plant And Equipment Gross	0.66	0.97	0.64	0.73	0.59	-0.63	0.75	0.64	-0.46	-0.83	0.48	0.61	0.94	0.54	0.12	0.61	0.82	0.92	-0.14	0.6	0.59	0.69	0.02	0.65		0.62
Total Current Assets	1.0	0.7	0.93	0.9	0.9	-0.97	0.9	0.93	-0.98	-0.92	0.95	1.0	0.81	0.78	0.48	1.0	0.67	0.44	-0.09	0.93	0.94	0.93	0.13	0.9	0.62

Click cells to compare fundamentals

Werewolf Therapeutics Account Relationship Matchups

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:

How To Invest In Werewolf

Details

Is Werewolf Stock a good investment?

Details

What is Werewolf Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.

You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.38)

Revenue Per Share

0.236

Quarterly Revenue Growth

(0.86)

Return On Assets

(0.22)

Return On Equity

(0.48)

The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Werewolf Current Deferred Revenue vs Common Stock Analysis

Current Deferred Revenue vs Common Stock

Current Deferred Revenue vs Common Stock Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Common Stock

Werewolf Therapeutics fundamental ratios Correlations

Werewolf Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Total Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Net Tangible Assets
Total Current Assets	- 0.97	Other Liab